We agree with Dr. Klok that thromboprophylactic dose low molecular weight heparin should be recommended for all the critically ill patients with 2019 novel coronavirus disease (COVID-19) pneumonia [1]. The very high cumulative incidence of thrombotic complications raises the question if therapeutic anticoagulation should be considered for severe COVID-19 pneumonia patients. As previously reported, patients with COVID-19 may show a wide range of neurologic manifestations, such as loss of consciousness, headache, seizures, ageusia, hyposmia and dysphagia. When clinicians evaluate patients with neurologic symptoms, they should consider SARS-CoV-2 infection as a differential diagnosis [2]. The most commonly described clinical features of COVID-19 have related to overwhelming respiratory symptoms and neurological symptoms have been underestimated and under-reported [3,4]. Recently, Ling Mao and colleagues showed that among 214 COVID-19 patients, 2.8% of them had ischemic stroke [2]. Here we present a case of COVID-19 pneumonia with cerebral hemorrhage. We propose that cerebral hemorrhage, in addition to ischemic stroke, can be a severe neurological manifestation in COVID-19 patients.A 68-year-old male patient with a history of atrial fibrillation on long-term warfarin presented with fever, cough and fatigue for 8 days, associated with shortness of breath for 5 days. He was admitted on Feb 5th, 2020 [illness day 8 (iDay) 8] to Wuhan Red Cross Hospital, a hospital designated to treat patients with severe COVID-19. The patient reported that he had been in contact with confirmed COVID-19 patients. His oropharyngeal swab was tested positive for SARS-CoV-2 by reverse-transcription polymerase-chain-reaction (RT-PCR) assays. No other respiratory viral pathogens were detected. His chest CT showed bilateral multifocal ground-glass opacities, consistent with of COVID-19 pneumonia. The laboratory results indicated elevated INR (1.6), prolonged PT (14.5 s) and normal creatinine (65 μmol/L). He had high levels of both D-dimer (70 mg/L), and C-reactive protein (77.6 mg/L). The patient was diagnosed with severe COVID-19 pneumonia and was admitted to ICU. His oxygen saturation (SpO2) decreased to 80% and he was started with non-invasive mechanical ventilation. He received supportive care; anti-viral treatment including arbidol (0.2 g, tid), lopinavir with ritonavir (LPV/RTV, 400 mg, bid) and recombinant human interferon beta-2b injection (5 million iu, qd); anti-bacterial treatment including moxifloxacin (250 mL, iv drip, qd); and low dose glucocorticoid treatment including methylprednisolone sodium succinate (MPSS, 40 mg, iv drip). Meanwhile, his warfarin was discontinued and he was started with subcutaneously treatment of low molecular weight heparin (LMWH, 4100 iu, qd; nadroparin calcium, AOSIDA, Hebei Changshan Biochemical Pharmaceutical Co., Ltd., 0.4 mL: 4100 iu; his weight 62 kg) for his atrial fibrillation.